The Weight-Loss Gold Rush: Legal and Regulatory Implications

Jul 11, 2024

17:10

Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:

Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
What needs to be done for GLP-1s to be covered
Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
Advice for investors and financiers who are considering entering the weight-loss medication market

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.